NCT00302666View on ClinicalTrials.gov

Bleeding Pattern Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,315

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

February 28, 2005

Conditions
Oral Contraceptive
Interventions
DRUG

Valette (Dienogest/EE30, BAY86-5038)

Oral contraceptive extended cycles

DRUG

Valette (Dienogest/EE30, BAY86-5038)

Oral contraceptive conventional cycles

Trial Locations (48)

10117

Berlin

10247

Berlin

12587

Berlin

13086

Berlin

13187

Berlin

17235

Neustrelitz

21073

Hamburg

22041

Hamburg

30159

Hanover

30459

Hanover

30952

Ronnenberg

33330

Gütersloh

36037

Fulda

38889

Blankenburg

39104

Magdeburg

39108

Magdeburg

39118

Magdeburg

39126

Magdeburg

39130

Magdeburg

58285

Gevelsberg

60322

Frankfurt am Main

60596

Frankfurt am Main

63128

Dietzenbach

63165

Mühlheim am Main

63225

Langen

65779

Kelkheim

65936

Frankfurt am Main

67292

Kirchheimbolanden

67346

Speyer

69412

Eberbach

85579

Neubiberg

86381

Krumbach

90491

Nuremberg

91315

Höchstadt A. D. Aisch

04720

Döbeln

01169

Dresden

01187

Dresden

04207

Leipzig

04299

Leipzig

04315

Leipzig

04808

Wurzen

06406

Bernburg

06917

Jessen

07607

Eisenberg

07545

Gera

07747

Jena

07768

Kahla

07318

Saalfeld

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00302666 - Bleeding Pattern Study | Biotech Hunter | Biotech Hunter